Enhanced blood glucose-lowering effect w/ anti-hyperglycaemic medicinal products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates & sulfonamide antibiotics. Reduced blood glucose-lowering effect w/ corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, oestrogens & progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (eg, epinephrine, salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (eg, clozapine & olanzapine) & PIs. Reduced or absent signs of adrenergic counter-regulation w/ sympatholytics eg, β-blockers, clonidine, guanethidine, reserpine. Insulin: Blood glucose-lowering effect of insulin may either be potentiated or weakened by β-blockers, clonidine, lithium salts or alcohol. May cause hypoglycaemia w/ pentamidine. Lixisenatide: May reduce the rate of absorption of orally administered drugs especially drugs of either narrow therapeutic ratio or drugs that require careful clinical monitoring; oral medicinal products that are particularly dependent on threshold conc for efficacy eg, antibiotics; gastro-resistant formulations containing substances sensitive to stomach degradation.